News Bayer left playing catch-up with BMS after Xarelto failure BMS' rival anticoagulant takes commanding market lead.
News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News AZ talks up Bydureon data, GLP-1 and glucagon combo AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
